206 filings
Page 4 of 11
8-K
uc99a fo70ywb4l8
19 Apr 21
Regulation FD Disclosure
4:22pm
8-K
bgbeettdelepfqp740k
19 Apr 21
OVID Provides Update on OV101 Program and the Prioritization of its Resources
8:31am
8-K
mv5ivrd
9 Apr 21
Regulation FD Disclosure
10:01am
8-K
u1wzsk
1 Apr 21
Termination of a Material Definitive Agreement
4:52pm
8-K
q11 bcau9j
30 Mar 21
Ovid Therapeutics Announces Closing of Agreement with Takeda for Global Development and Commercialization of Soticlestat
8:05am
S-8
83qvhsgtxfjx0 rodx
18 Mar 21
Registration of securities for employees
12:00am
CT ORDER
vsypfoql7za hmeqja5
18 Mar 21
Confidential treatment order
12:00am
8-K
mptgljsjneow
15 Mar 21
Ovid Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update for 2021
8:05am
8-K
fq7k5u2j8 llyr48t72f
3 Mar 21
Regulation FD Disclosure
10:05am
8-K
wdc 5ywu7r0zw
3 Mar 21
Entry into a Material Definitive Agreement
7:05am
8-K
xzhu6jm 313t
21 Dec 20
Departure of Directors or Certain Officers
5:26pm
8-K
wm02f2mnu 897
1 Dec 20
Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary Endpoint
5:19pm
EFFECT
qohi2oafth l6
23 Nov 20
Notice of effectiveness
12:18am
424B5
1t503ufbwllbxgt0 9ab
20 Nov 20
Prospectus supplement for primary offering
4:23pm
UPLOAD
jmi3sks
18 Nov 20
Letter from SEC
12:00am
CORRESP
cuxtjnoaag3t
18 Nov 20
Correspondence with SEC
12:00am
8-K
fnkrn
12 Nov 20
Ovid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
4:28pm